Peptides
5-Amino-1MQ
Also called 5-amino-1MQ · 1MQ · 5-Amino-1-methylquinolinium
People look at 5-Amino-1MQ for fat loss without a stimulant or a weekly appetite injection. That appeal comes from an experimental metabolism target and animal results; reliable human weight-loss benefits and an effective dose have not been established.
Dosage & duration
One author’s published oral-use example, not a validated human regimen.
Jay Campbell · reported capsule use
Reported use · unapproved regimen- Dose
- 50–150 mg total per day
- How often
- Once daily, oral capsules
- How long
- 20–30 days, then a 1–2-week break in this example
The author describes personal use; this does not establish a common dose, proven benefit or safe course.
No human dose-response study in the checked sources validates this amount.
Why it attracts interest
A fat-loss idea with a human evidence gap
-
The appeal
People seek fat-loss support without a stimulant or weekly appetite injection.
-
The animal finding
The foundational weight-loss experiment used injections in mice.
-
The capsule question
That experiment does not establish human capsule benefits or an effective dose.
Why it is marketed for fat loss
5-Amino-1MQ blocks NNMT, an enzyme involved in cellular metabolism. The attraction is changing how the body handles energy rather than simply making someone less hungry. Mouse findings are a reason for research, not proof that a capsule accelerates human fat loss.
Where the capsule numbers come from
Clinic and seller pages publish oral amounts, while the foundational obesity experiment used injections in mice. A 50 mg capsule example is useful for understanding the market, but it is not a clinically established dose or a conversion from that animal experiment.
Comparing it with GLP-1 medicines
It is not a GLP-1 and it is not a peptide, despite often appearing in peptide catalogues. There is no verified head-to-head human trial here showing that it adds to a GLP-1 or preserves more muscle during weight loss.
Model details: 5-Amino-1MQ · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Human route/formulation, systemic exposure, absorption and terminal kinetics were not established by the reviewed source. Cell permeability cannot supply oral bioavailability.
- Neelakantan et al. 2018: NNMT inhibitors and diet-induced obesity
Cell permeability and mouse efficacy experiments do not provide matched human systemic Cmax, absorption or elimination parameters.
5-amino-1mq-relative-timing-2026-10 · version 1
Common questions
Is 5-Amino-1MQ a peptide?
No. It is a small molecule that inhibits NNMT.
Does a 50 mg capsule have proven weight-loss benefits?
The checked human evidence does not establish that. The displayed amount is an attributed clinic example.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- A sought-after benefit, not a proven human effect.
- Common format online
- Capsule claims are not the route used in the foundational mouse study.
- Important comparison
- Different target and much less clinical evidence.
- 1. Neelakantan et al. — NNMT inhibition in mice
Original obesity study used injected 5-amino-1MQ in mice, not human capsules.
- 2. Neelakantan et al. 2018: NNMT inhibitors and diet-induced obesity
Cell permeability and mouse efficacy experiments do not provide matched human systemic Cmax, absorption or elimination parameters.
Keep reading
Related compounds and examples
Related compounds
AICAR
AICAR for endurance: where the exercise-pill claim comes from, reported amounts and comparison with Cardarine.
SLU-PP-332
SLU-PP-332 draws interest for fat loss and endurance—the “exercise mimetic” idea. Mouse studies showed exercise-like metabolic changes, but they do not show that it replaces training or produces the same results in people. Human online experiments remain uncontrolled reports.
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.